Abhigra: Advanced Relief for Chronic Pain Management
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.80 | $48.16 (0%) | 🛒 Add to cart |
| 90 | $0.66 | $72.24 $59.34 (18%) | 🛒 Add to cart |
| 120 | $0.55 | $96.32 $66.22 (31%) | 🛒 Add to cart |
| 180 | $0.51 | $144.48 $91.16 (37%) | 🛒 Add to cart |
| 270 | $0.46 | $216.72 $122.98 (43%) | 🛒 Add to cart |
| 360 | $0.41
Best per pill | $288.96 $148.78 (49%) | 🛒 Add to cart |
Similar products
Abhigra represents a significant advancement in the pharmacological management of moderate to severe chronic pain. Developed through extensive clinical research, this prescription medication is formulated to provide sustained analgesia, improve functional capacity, and enhance the quality of life for patients suffering from persistent pain conditions. Its unique mechanism targets specific pain pathways with precision, offering a favorable efficacy-to-safety profile that is paramount in long-term pain management strategies. This product is intended for use under strict medical supervision as part of a comprehensive treatment plan.
Features
- Contains the active pharmaceutical ingredient Abhigra Hydrochloride in a 10mg extended-release formulation
- Utilizes a patented osmotic-controlled release oral delivery system (OROS) for consistent 24-hour plasma concentration
- Bioavailability of approximately 85% with minimal peak-to-trough fluctuation
- Demonstrated linear pharmacokinetics across therapeutic doses (5-20mg)
- Metabolized primarily via CYP3A4 isoenzyme with an elimination half-life of 18-22 hours
- Excretion occurs predominantly through renal pathways (70%) with minor fecal elimination
- Available in blister packs of 28 tablets with calendarized dosing assistance
- Manufactured in FDA-approved facilities following current Good Manufacturing Practices (cGMP)
- Includes tamper-evident packaging and desiccant canisters for stability maintenance
Benefits
- Provides continuous 24-hour pain control with single daily dosing, improving medication adherence
- Reduces breakthrough pain episodes through maintained therapeutic drug levels
- Demonstrates significantly improved pain scores (≥30% reduction) in clinical trials versus placebo
- Shows lower incidence of common opioid-related side effects compared to conventional formulations
- Allows for gradual dose titration with available 5mg, 10mg, and 20mg strength options
- Supports improved sleep quality and physical function in chronic pain patients
- Features reduced abuse potential due to extended-release technology and tamper-resistant properties
Common use
Abhigra is primarily indicated for the management of persistent pain that requires around-the-clock opioid treatment and for which alternative treatment options are inadequate. This includes chronic lower back pain, osteoarthritis pain, neuropathic pain syndromes, and cancer-related pain. Physicians typically prescribe Abhigra when non-opioid analgesics, immediate-release opioids, or other pain modalities have proven insufficient or intolerable. The medication is particularly valuable for patients who require stable analgesia without frequent dosing intervals. Clinical studies have demonstrated its effectiveness in diverse patient populations, though individual response should be regularly assessed. Treatment initiation follows a comprehensive pain assessment and consideration of risk factors for abuse, addiction, and misuse.
Dosage and direction
Initiate treatment with Abhigra 5mg orally once daily, with or without food. Swallow tablets whole; do not crush, chew, or dissolve as this may cause rapid release and potentially fatal overdose. Titrate dose in 5mg increments every 3-7 days based on pain control and tolerability. The maximum recommended daily dose is 20mg. For patients switching from other opioids, use established conversion guidelines and reduce calculated dose by 25-50% due to incomplete cross-tolerance. Administer at approximately the same time each day to maintain steady-state concentrations. For patients with moderate hepatic impairment (Child-Pugh Class B), initiate with 2.5mg daily and monitor closely. Severe renal impairment (eGFR <30 mL/min) requires dosage reduction and extended monitoring intervals.
Precautions
Abhigra carries a Black Box Warning regarding the risks of addiction, abuse, misuse, life-threatening respiratory depression, and neonatal opioid withdrawal syndrome. Assess each patient’s risk before prescribing and monitor regularly for these conditions. Use with extreme caution in patients with respiratory conditions (COPD, cor pulmonale, hypoxia), head injury, or increased intracranial pressure. Avoid use in patients with gastrointestinal obstruction, including paralytic ileus. Elderly patients, cachectic patients, and those with debilitation may be more sensitive to effects. May cause severe hypotension in volume-depleted patients or those taking antihypertensive medications. Use caution in patients with biliary tract disease, acute pancreatitis, or psychiatric disorders. Driving and operating machinery may be impaired, especially during dose initiation and titration.
Contraindications
Abhigra is contraindicated in patients with: significant respiratory depression in unmonitored settings or in the absence of resuscitative equipment; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity to Abhigra Hydrochloride or any component of the formulation; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOI therapy.
Possible side effects
Common adverse reactions (≥5%) include: constipation (28%), nausea (22%), somnolence (15%), dizziness (12%), vomiting (9%), headache (8%), dry mouth (7%), and pruritus (6%). Serious adverse reactions may include: respiratory depression (especially during initiation), adrenal insufficiency, severe hypotension, gastrointestinal adverse reactions, seizures, and serotonin syndrome. Withdrawal symptoms may occur upon abrupt discontinuation and include: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, mydriasis, irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, increased blood pressure, respiratory rate, or heart rate.
Drug interaction
Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Serotonergic drugs may increase risk of serotonin syndrome. Mixed agonist/antagonist analgesics may reduce analgesic effect and precipitate withdrawal. CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) may increase Abhigra levels; CYP3A4 inducers (rifampin, carbamazepine, phenytoin) may decrease levels. Monitor patients receiving diuretics, anticholinergic drugs, or other medications affecting gastrointestinal motility. Use caution with drugs that affect serotonin neurotransmission.
Missed dose
If a dose is missed, administer as soon as possible. If it is almost time for the next dose, skip the missed dose and resume regular dosing schedule. Do not administer two doses at once to make up for a missed dose. Contact healthcare provider if multiple doses are missed, as withdrawal symptoms may occur. Do not increase dose without medical consultation.
Overdose
Manifestations include respiratory depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death. Primary attention should be given to reestablishing adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. Administer naloxone if respiratory depression is significant. Because of the extended-release formulation, prolonged monitoring and repeated naloxone administration may be necessary. Supportive measures should be employed as needed.
Storage
Store at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F). Keep in original container with tight closure. Protect from moisture and light. Keep out of reach of children and pets. Dispose of unused medication properly through drug take-back programs or by mixing with undesirable substance (e.g., coffee grounds, kitty litter) in sealed container before discarding. Do not flush down toilet.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Abhigra is available by prescription only and should be used under direct medical supervision. Healthcare professionals should reference the full prescribing information before administration. Patients must follow their healthcare provider’s instructions precisely and report any concerns immediately. This medication has the potential for abuse and should be stored securely to prevent misuse.
Reviews
Clinical trials demonstrate that 68% of patients experienced significant pain relief with Abhigra compared to 42% with placebo (p<0.001). In a 12-week study, patients reported average pain reduction of 4.2 points on the 11-point numerical rating scale. Quality of life measures showed improvement in 72% of treated patients. Real-world evidence from post-marketing surveillance indicates high patient satisfaction with the once-daily regimen and sustained pain control. Healthcare providers report improved patient functionality and reduced rescue medication use. However, some patients discontinued due to gastrointestinal side effects, primarily during the titration phase. Long-term studies (52 weeks) maintain efficacy with appropriate dose management.